BioTime (BTX) Announces Issuance Of 14 Patents In The Fields Of Regenerative Medicine, And Cancer Diagnosis And Therapy
7/14/2014 8:22:33 AM
ALAMEDA, Calif.--(BUSINESS WIRE)--BioTime, Inc. (NYSE MKT:BTX) announced today the issuance of 14 new patents to BioTime and its subsidiary companies. The patents issued in Australia, Canada, China, Japan, and the United States, cover a wide range of core technologies foundational to BioTime’s businesses. The new patents add to the largest known patent estate under one corporate umbrella in the field of pluripotent stem cell technology known as “regenerative medicine” with over 600 existing patents and patent applications owned or licensed to BioTime and its subsidiaries worldwide.
Help employers find you! Check out all the jobs and post your resume.
comments powered by